KRS Capital Management LLC Boosts Stock Position in Abbott Laboratories $ABT

KRS Capital Management LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,001 shares of the healthcare product maker’s stock after acquiring an additional 250 shares during the period. Abbott Laboratories makes up 0.7% of KRS Capital Management LLC’s investment portfolio, making the stock its 28th biggest holding. KRS Capital Management LLC’s holdings in Abbott Laboratories were worth $1,088,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABT. Brighton Jones LLC raised its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Wealthcare Advisory Partners LLC raised its stake in Abbott Laboratories by 8.4% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 13,282 shares of the healthcare product maker’s stock valued at $1,762,000 after acquiring an additional 1,024 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Abbott Laboratories by 17.0% during the 1st quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock worth $5,103,000 after buying an additional 5,590 shares in the last quarter. Integrated Advisors Network LLC raised its stake in shares of Abbott Laboratories by 30.9% during the 1st quarter. Integrated Advisors Network LLC now owns 26,003 shares of the healthcare product maker’s stock worth $3,449,000 after buying an additional 6,131 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. purchased a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $297,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABT has been the subject of a number of analyst reports. The Goldman Sachs Group increased their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Royal Bank Of Canada increased their target price on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Evercore ISI increased their target price on Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a research note on Tuesday. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Leerink Partners began coverage on Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $146.24.

Abbott Laboratories Stock Performance

ABT opened at $133.24 on Friday. The stock has a market cap of $231.90 billion, a P/E ratio of 16.70, a P/E/G ratio of 2.55 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The stock’s 50 day simple moving average is $132.44 and its 200 day simple moving average is $131.52. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is 29.57%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.